Horama Company
Horama develops gene therapies for rare inherited ocular diseases.
Number Of Exists:
Series B
Technology:
Neurological Disorders
Last Funding Type:
Series B
Investors Number:
9
Industry:
Gene Therapy
Founded Date:
2014
Investor Type:
Company
Employee Number:
11-50
Investment Stage:
N/A
Total Funding:
â¬27.1M
Headquarters:
Paris, Ile-de-France, France
Estimated Revenue:
$1M to $10M
Funding Status:
Early Stage Venture